



Docket No.: 19603/4071 (CRF D-2598A)

PATENT

#8
Date 4/20/02

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Vivian E. Mack Strong et al.

Serial No. : 09/782,936

Cnfrm. No. : 1665

Filed : February 14, 2001

For : USE OF COX-2 INHIBITORS TO TREAT
SEPSIS, COMPLICATIONS THEREOF,
AND EP RECEPTOR MODULATION

Examiner:
M.C. Wilson

Art Unit:
1632

TECH CENTER 1600/2900

APR 19 2002

RECEIVED

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, Virginia 22202

Dear Sir:

In response to the written communications dated March 26, 2002, and January 16, 2002, imposing an election of species requirement, applicants hereby elect, with traverse, the drug species identified as a small molecule. The elected species is readable on all of the claims of previously-elected Group I (i.e., claims 1, 2, 9, 12, and 15).

Respectfully submitted,

Date:

April 11, 2002

Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office P.O. BOX 2327
Arlington, VA 22202, on the date below.

Date

4/12/02

Jo Ann Whalen